Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reduced Segmentation of Lesions Is Comparable to Whole-Body Segmentation for Response Assessment by PSMA PET/CT: Initial Experience with the Keyhole Approach.
Hartrampf PE, Krebs M, Peter L, Heinrich M, Ruffing J, Kalogirou C, Weinke M, Brumberg J, Kübler H, Buck AK, Werner RA, Seitz AK. Hartrampf PE, et al. Among authors: kubler h. Biology (Basel). 2022 Apr 26;11(5):660. doi: 10.3390/biology11050660. Biology (Basel). 2022. PMID: 35625388 Free PMC article.
68Ga-PSMA I&T PET/CT for primary staging of prostate cancer.
Cytawa W, Seitz AK, Kircher S, Fukushima K, Tran-Gia J, Schirbel A, Bandurski T, Lass P, Krebs M, Połom W, Matuszewski M, Wester HJ, Buck AK, Kübler H, Lapa C. Cytawa W, et al. Among authors: kubler h. Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):168-177. doi: 10.1007/s00259-019-04524-z. Epub 2019 Sep 16. Eur J Nucl Med Mol Imaging. 2020. PMID: 31529265
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Hartrampf PE, Weinzierl FX, Buck AK, Rowe SP, Higuchi T, Seitz AK, Kübler H, Schirbel A, Essler M, Bundschuh RA, Werner RA. Hartrampf PE, et al. Among authors: kubler h. Eur J Nucl Med Mol Imaging. 2022 Jul;49(9):3269-3276. doi: 10.1007/s00259-022-05744-6. Epub 2022 Mar 4. Eur J Nucl Med Mol Imaging. 2022. PMID: 35243517 Free PMC article.
Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens.
Cytawa W, Kircher S, Kübler H, Werner RA, Weber S, Hartrampf P, Bandurski T, Lass P, Połom W, Matuszewski M, Wester HJ, Lapa C, Rosenwald A, Seitz AK, Buck AK. Cytawa W, et al. Among authors: kubler h. Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3938-3949. doi: 10.1007/s00259-022-05831-8. Epub 2022 May 12. Eur J Nucl Med Mol Imaging. 2022. PMID: 35556160
Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up.
Hartrampf PE, Seitz AK, Weinzierl FX, Serfling SE, Schirbel A, Rowe SP, Kübler H, Buck AK, Werner RA. Hartrampf PE, et al. Among authors: kubler h. Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4262-4270. doi: 10.1007/s00259-022-05853-2. Epub 2022 Jun 2. Eur J Nucl Med Mol Imaging. 2022. PMID: 35650263 Free PMC article.
mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease.
Hartrampf PE, Bundschuh RA, Weinzierl FX, Serfling SE, Kosmala A, Seitz AK, Kübler H, Buck AK, Essler M, Werner RA. Hartrampf PE, et al. Among authors: kubler h. Eur J Nucl Med Mol Imaging. 2022 Nov;49(13):4727-4735. doi: 10.1007/s00259-022-05910-w. Epub 2022 Jul 19. Eur J Nucl Med Mol Imaging. 2022. PMID: 35852555 Free PMC article.
164 results